Finn
ARGX Biotechnology · Rare disease · Autoimmune · Profitable biotech · Thesis updated October 25, 2026

VYVGART sales reach new highs as label expands

01 Running thesis

A rare disease winner with momentum

argenx has evolved into a highly profitable drug company. VYVGART continues to exceed expectations, producing $1.7 billion of product net sales in the third quarter of 2026. The recent approval for seronegative generalized myasthenia gravis is creating a positive halo effect, increasing prescribers across all patient types.

The bull case relies on adding patient groups while maintaining pricing power. Management is targeting up to five new launches in 2027 to support their long-term growth plan. Near-term catalysts include the pivotal EMPASSION readout for empasiprubart in December 2026 and a pediatric FDA decision in February 2027.

The bear case centers on clinical execution and pipeline setbacks. While recent data supports a regulatory filing for immune-mediated necrotizing myopathy, the FDA is requiring an additional study for dermatomyositis. Furthermore, the company halted a trial in Sjögren's syndrome due to futility. Investors are closely watching trial outcomes to justify the current valuation.

Oct 2026▲Q3 2026 product net sales reached $1.7 billion, up 54% year over year. The pipeline outlook was mixed, with plans for an IMNM filing by year-end offset by a new trial requirement for DM and a halted trial in Sjögren's syndrome.
Jul 2026▲Q2 2026 product net sales reached $1.5 billion, up 60% year over year. VYVGART received FDA approval for seronegative gMG, becoming the first treatment approved across all serotypes.
Mar 2026▲The 2025 20-F confirmed more than 19,000 patients on VYVGART globally, $4.2 billion of 2025 net sales, and $1.3 billion of profit. It also added expected base exclusivity dates of December 2033 in the U.S. and August 2032 in the EU.
Feb 2026▲Q4 2025 product net sales reached $1.3 billion, and full-year sales rose 90% to $4.2 billion. The FDA CIDP worsening review ended with label guidance, removing a key safety overhang.
Oct 2025▲Q3 2025 crossed $1 billion of quarterly VYVGART sales for the first time. Gross-to-net adjustments stabilized, and the seronegative gMG Phase III study met its primary endpoint.
Jul 2025▲Q2 2025 sales reached $949 million, with 15,000 global VYVGART patients and 2,500 CIDP patients. A FAERS CIDP worsening signal became a new risk to monitor, though management cited a low event rate.
May 2025▲Q1 2025 sales reached $790 million. The prefilled syringe launch began in the U.S. and Germany, with half of early starts coming from first-time VYVGART users.
Mar 2025▲The 2024 20-F confirmed argenx earned $833 million in 2024, earlier than the prior profit expectation. It also formalized Vision 2030, including a goal of 10 labeled indications.
02 Business model

High-priced drugs for rare diseases

argenx sells biologic medicines for rare autoimmune diseases. These drugs are complex antibody therapies, not simple pills. The main product is efgartigimod, sold as VYVGART for intravenous use and VYVGART Hytrulo for under-the-skin injection.

Most revenue comes from treating generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. Both are serious immune-driven nerve and muscle diseases. Payers often accept high prices because the patient populations are small and the medical need is severe.

The shift to prefilled syringes lets more patients self-administer at home. This format grows volume but shifts U.S. reimbursement from Medicare medical coverage to pharmacy coverage. This shift initially raised gross-to-net discounts earlier in the year. Management notes that these adjustments and U.S. net pricing stabilized in the third quarter, easing concerns about margin pressure.

03 Product portfolio

One engine with several shots

Cash cow

VYVGART and VYVGART Hytrulo in gMG

The core franchise is driving current revenue. The label now covers all adult patients, including those who are triple seronegative.

Growth engine

VYVGART Hytrulo in CIDP

CIDP is a major growth driver. Early launch momentum was strong, and investors are watching to see if growth continues beyond initial switch patients.

Option

Efgartigimod in myositis

Positive ALKIVIA data supports a regulatory filing for IMNM by year-end. However, dermatomyositis will require an additional registrational study.

Option

Empasiprubart

This is a second pipeline antibody in registrational studies. The pivotal multifocal motor neuropathy readout in December 2026 is a major test.

Option

FB102

Acquired from Forte, this asset demonstrated positive Phase II results in celiac disease. It is now advancing into Phase III studies.

Option

ARGX-119

Currently in a registrational study for congenital myasthenic syndrome. It provides argenx another opportunity outside the VYVGART franchise.

04 Business segments

United States drives the revenue

United States86%growing fast
Rest of world9%growing fast
Japan5%modest

This mix uses Q3 2026 product net sales by region: $1.5 billion in the U.S., $158 million in rest of world, $81 million in Japan, and $11 million from product supply to Zai Lab in China. The company is highly concentrated in VYVGART.

05 Risk factors

What could break the story

CIDP growth slows after early switch patients

High impact · Medium odds

The early CIDP launch benefited from patients switching from existing therapies. That pool may not last forever. If new patient starts begin to slow down, the market may question the total size of the CIDP opportunity.

We watchTrack CIDP patient additions, new starts, and any split between switch patients and biologic-naive patients.

Gross-to-net discounts pressure profit margins

Medium impact · Medium odds

Self-injection shifted more U.S. use into pharmacy benefit channels, which raised gross-to-net discounts earlier in the year. While discounts stabilized in the third quarter, a renewed increase would pressure profits.

We watchWatch quarterly comments on U.S. net pricing, pharmacy benefit mix, and gross-to-net adjustments.

Pipeline readouts fail to show superiority

High impact · Medium odds

argenx relies on repeated clinical wins to expand its label. Following the halt of the UNITY trial, attention turns to whether empasiprubart can demonstrate superiority, not just non-inferiority, to existing treatments in upcoming readouts.

We watchThe December 2026 empasiprubart readout in multifocal motor neuropathy.

Biosimilars arrive after exclusivity ends

High impact · Low odds

VYVGART has a long runway, but not a permanent one. The base regulatory exclusivity period is expected to run until December 2033 in the U.S. and August 2032 in the EU.

We watchMonitor patent challenges, biosimilar filings, and any updates to U.S. and EU exclusivity timelines.
06 Quick answers

In one breath

What does argenx sell?

argenx sells VYVGART and VYVGART Hytrulo, versions of efgartigimod. They are antibody medicines used for rare immune nerve and muscle diseases such as gMG and CIDP.

Why is VYVGART important to ARGX stock?

VYVGART is the main revenue engine. It generated $1.7 billion of product net sales in the third quarter of 2026 and drives the company's profitability.

What changed with the seronegative gMG approval?

The FDA expanded VYVGART and VYVGART Hytrulo to all adult gMG patients in the U.S. That includes triple seronegative patients who previously had no approved treatment option.

What is the biggest risk for argenx now?

The main near-term risk is whether CIDP keeps growing after early switch patients. A second risk is clinical trial failure, as seen with the recent halt of the Sjögren's syndrome trial.

07 Research standards

Sources and research notes

This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.

Thesis reviewed
October 25, 2026
Score data
November 15, 2026
Reviewed by
Shivam Bharuka
  1. argenx Q3 2026 earnings transcript
  2. argenx 2025 Form 20-F
08 Explore the industry

Comparable Biotechnology companies

Companies near argenx SE in Finn's Biotechnology industry ranking.

Get started with Finn today